Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.61 |
| ▸ | HK1 | P19367 | 1/20 | 0.61 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | BCKDK | O14874 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8878527 | 0.88 | MAPT (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL2897835 | 0.88 | MAPT (0.67) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL12553307 | 0.87 | MAPT (0.69) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL11148066 | 0.87 | MAPT (0.65) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL13659632 | 0.83 | MAPT (0.72) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL5038192 | 0.83 | MAPT (0.65) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL3454727 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL2723054 | 0.78 | BCKDK (0.75) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A | |
| SCHEMBL5234250 | 0.76 | MAPT (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2USP2 | |
| SCHEMBL2279755 | 0.75 | BCKDK (0.77) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | claimed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-20090247513-A1 | BENZOTHIOPHENE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247513-A1 | BENZOTHIOPHENE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2006-11-23 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
| US-5608074-A | Process for the synthesis of 5-amino tetrazole derivatives | WARNER-LAMBERT COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3832/4885MAPT 4834/4885HPGD 2422/4885 |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3593/4885MAPT 4846/4885HPGD 2481/4885 |
| US-20090247513-A1 | BENZOTHIOPHENE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | TOP2A, TOP1, TOP2B | ALDH1A1 2608/4885MAPT 496/4885HPGD 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.